Successful desensitization under antihistamine suppression in a case with urticaria due to osimertinib

Abstract

Introduction

Osimertinib is an approved therapy for patients with a Thr790met (T790M) mutation diagnosed with non-small cell lung cancer (NSCLC) that progresses during epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. However, in 7–13% of patients, drug-related side effects lead to discontinuation of osimertinib treatment. In such cases, osimertinib desensitization is a treatment option that can be considered.

Case report

A 59-year-old female patient, who was followed up with the diagnosis of stage 4 NSCLC, was consulted to the allergy clinic because of urticaria. The patient developed urticaria plaques 20 h after the third dose of osimertinib tablet.

Management & outcome

With the diagnosis of osimertinib-induced urticaria, desensitization was planned for the patient. Treatment was started with a dose of 0.1 mg/day osimertinib. The procedure was completed in approximately 50 days, and a dose of 80 mg/day was reached with antihistamine suppression.

Discussion

Here, a successful osimertinib desensitization in a patient with a history of osimertinib-related type 1 allergic reaction is reported. Osimertinib desensitization is a treatment option that should be considered in cases where treatment has to be ceased due to drug-related side effects.

Keywords

Osimertinib desensitization urticaria allergy cancer drug immunotherapy

Get full access to this article

View all access options for this article.

References

Maemondo

Inoue

Kobayashi

, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380–2388.

Kobayashi

Boggon

Dayaram

, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786–792.

Soria

Ohe

Vansteenkiste

, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018; 378: 113–125.

Mok

Y-L

Ahn

M-J

, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017; 376: 629–640.

Makimoto

Nishi

Kawakado

, et al. Successful desensitization treatment with osimertinib after the development of osimertinib—induced urticaria in a patient undergoing treatment for non-small cell lung cancer harboring the EGFR T790M mutation. Intern Med 2020; 59: 2161–2164.

Hirabayashi

Fujimoto

Satsuma

, et al. Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report. Invest New Drugs 2018; 36: 952–954.

Watanabe

Mimura

Fukushima

, et al. Desensitization therapy for osimertinib in patients who developed toxic erythema—two case reports. Gan To Kagaku Ryoho 2019; 46: 961–963.

Naranjo

Busto

Sellers

, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–245.

Castells Guitart

. Rapid drug desensitization for hypersensitivity reactions to chemotherapy and monoclonal antibodies in the 21st century. J Investig Allergol Clin Immunol 2014; 24: 72–79.